Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries SciSparc Ltd. - Ordinary Shares (NQ: SPRC ) 0.2505 +0.0213 (+9.29%) Streaming Delayed Price Updated: 11:41 AM EDT, Oct 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about SciSparc Ltd. - Ordinary Shares < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome July 08, 2022 SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of... Via Benzinga SciSparc Announces Buyback Equal To 12% Of Float July 07, 2022 SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par... Via Benzinga Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd. July 07, 2022 NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... From Traders News Source Via AccessWire SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome June 30, 2022 SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study... Via Benzinga SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome June 29, 2022 SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed... Via Benzinga SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome June 29, 2022 TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd. Via Benzinga SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder June 23, 2022 The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment Via Benzinga SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins June 15, 2022 JV Targets Potential Drugs for Cancers and Infectious Diseases Via Benzinga R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions June 29, 2022 Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... Via FinancialNewsMedia SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray June 28, 2022 The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain. Via Benzinga SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment June 24, 2022 SciSparc Ltd. Via Benzinga Initial Positive Results For Cocaine Addiction Treatment Announced June 08, 2022 Photo by Annie Spratt on Via Benzinga SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc. June 07, 2022 SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction Via Benzinga SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems May 31, 2022 SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology Via Benzinga 93 Biggest Movers From Yesterday June 14, 2022 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... Via Benzinga SciSparc Announces $10M Private Offering May 27, 2022 SciSparc Ltd. Via Benzinga 70 Stocks Moving In Monday's Mid-Day Session June 13, 2022 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... Via Benzinga Central Nervous System (CNS) Therapeutics Global Market Expected to Reach $154 Billion By 2027 June 09, 2022 Palm Beach, FL – June 9, 2022 – FinancialNewsMedia.com News Commentary – The central nervous system (CNS) consists of the brain and spinal cord and brain and nervous system problems are more common and... Via FinancialNewsMedia EXCLUSIVE: SciSparc' Board To Review Potential Strategic Transactions June 09, 2022 SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focused on the endocannabinoid system, plans to review potential strategic transactions. Via Benzinga Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies June 08, 2022 The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. Via Benzinga Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics June 07, 2022 Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... Via FinancialNewsMedia Exposures COVID-19 SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction June 02, 2022 SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine... Via Benzinga SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction June 02, 2022 No dedicated treatment currently available for cocaine addiction Via Benzinga Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC). June 02, 2022 NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC). From Aegis Capital Corp. Via AccessWire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday June 01, 2022 Good morning, investors! Busy traders are already at work this morning as we go over the biggest pre-market stock movers for Wednesday. Via InvestorPlace 70 Biggest Movers From Friday May 31, 2022 Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... Via Benzinga SciSparc Gets Ethics Committee Approval In Germany And Israel Sites To Conduct A Phase IIb Trial In Tourette Syndrome May 27, 2022 Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga 20 Stocks Moving in Friday's Pre-Market Session May 27, 2022 Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma. Via Benzinga 88 Biggest Movers From Yesterday May 27, 2022 Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. Via Benzinga Mid-Afternoon Market Update: Dow Surges 575 Points; Apyx Medical Shares Spike Higher May 26, 2022 U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 575 points on Thursday. Via Benzinga < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.